CBIO (Crescent Biopharma) Total Equity: $183.85 Mil (As of Mar. 2026)


CBIO Crescent Biopharma Inc CBIO
10 GF Score
Price $17.07
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Total Equity?

Crescent Biopharma CBIO +0.06% 10 Total Equity is $183.85 Mil as of Mar. 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Crescent Biopharma's total equity for the quarter that ended in Mar. 2026 was $183.85 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Crescent Biopharma Total Equity Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Total Equity Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Total Equity
-15.48 203.01

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial 0.00 139.25 116.64 203.01 183.85
CBIO
10GF Score
Crescent Biopharma Inc CBIO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Crescent Biopharma's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=240.293-37.281
=203.01

Crescent Biopharma's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=199.13-15.283
=183.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $183.85 Mil mean?
Crescent Biopharma (CBIO) has a Total Equity of $183.85 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Crescent Biopharma and its competitors.
Is Crescent Biopharma's Total Equity too high?
Crescent Biopharma's current Total Equity is $183.85 Mil. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Total Equity compare to KYTX and ZURA?
Crescent Biopharma's Total Equity of $183.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Crescent Biopharma and its competitors. Crescent Biopharma's current Total Equity is $183.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current Total Equity of $183.85 Mil. The current Total Equity is $183.85 Mil. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current Total Equity is $183.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges C68:Germany
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for CBIO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.07
Price